Primary Endpoint Met in Corcepl Phase 3 Ovarian Cancer Trial

 

• Relacorilant plus nab-paclitaxel improved progression-free and overall survival and did not increase side effect burden
• Results will support a New Drug Application (NDA) in the United States and a Marketing Authorization Application (MAA) in Europe
• Relacorilant plus nab-paclitaxel has the potential to become a new standard of care for patients with platinum-resistant ovarian cancer

https://www.businesswire.com/news/home/20250331748780/en/Primary-Endpoint-Met-in-Corcepts-Pivotal-Phase-3-ROSELLA-Trial-of-Relacorilant-in-Patients-with-Platinum-Resistant-Ovarian-Cancer